A Retrospective Study to Examine Healthcare Costs Related to Cardiovascular Events in Individuals with Hyperlipidemia

Advances in Therapy

Volumn 32, Issue 11, 2015, Pages 1104-1116

  Henk, Henry J ^a   Paoli, Carly J ^b   Gandra, Shravanthi R ^b  

^a OPTUM   (United States)

^b AMGEN INC   (United States)

Author keywords

Atherosclerosis; Cardiology; Cardiovascular disease; Coronary diseases; Healthcare costs; Hypercholesterolemia; Hyperlipidemia

Indexed keywords

ADULT; AGED; AMBULATORY CARE; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CORONARY ARTERY BYPASS GRAFT; COST OF ILLNESS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; RETROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; ADOLESCENT; CARDIOVASCULAR DISEASES; CORONARY DISEASE; ECONOMICS; HOSPITALIZATION; HYPERLIPIDEMIAS; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CORONARY DISEASE; FEMALE; HEALTH EXPENDITURES; HOSPITALIZATION; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84948575880     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0264-7     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol–United States, 1999–2002 and 2005–200. MMWR. 2011;60(4):109–14.
2. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther. 2009;31(2):236–44.
3. Stauffer ME, Weisenfluh L, Morrison A. Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. Vasc Health Risk Manage. 2013;9:671–80.
4. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–73.
5. National Center for Health Statistics. Health, United States, 2013: with special feature on prescription drugs. Hyattsville: National Center for Health Statistics; 2013.
6. World Health Organization. The global burden of disease: 2004 update. 2008 Available from: http://www.who.int/topics/global_burden_of_disease/en/. Accessed 28 Aug 2015.
7. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–292.
8. Chapman RH, Liu LZ, Girase PG, Straka RJ. Determining initial and follow-up costs of cardiovascular events in a US managed care population. BMC Cardiovasc Disorders. 2011;11:11.
9. Demaerschalk BM, Hwang HM, Leung G. US cost burden of ischemic stroke: a systematic literature review. AJMC. 2010;16(7):525–33.
10. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke; Journal Cerebral Circ. 2011;42(1):227–76.
11. Godwin KM, Wasserman J, Ostwald SK. Cost associated with stroke: outpatient rehabilitative services and medication. Topics Stroke Rehab. 2011;18(Suppl 1):676–84.
12. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58(23):2432–46.
13. Hayes J, Vogel B, Reker DM. Factors associated with VHA costs of care for first 12 months after first stroke. J Rehab Res Dev. 2008;45(9):1375–84.
14. Zorowitz RD, Chen E, Tong KB, Laouri M. Costs and rehabilitation use of stroke survivors: a retrospective study of Medicare beneficiaries. Topics Stroke Rehab. 2009;16(5):309–20.
15. Nichols GA, Bell TJ, Pedula KL, O’Keeffe-Rosetti M. Medical care costs among patients with established cardiovascular disease. Am J Managed Care. 2010;16(3):e86–93.
16. Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovasc Diabetol. 2009;8:53.
17. Doan QV, Gleeson M, Kim J, Borker R, Griffiths R, Dubois RW. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Op. 2007;23(7):1561–9.
18. Duh MS, Fulcher NM, White LA, et al. Costs associated with cardiovascular events in patients with hypertension in US managed care settings. J Am Soc Hypertension. 2009;3(6):403–15.
19. Tung CY, Granger CB, Sloan MA, et al. Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries study. Circulation. 1999;99(3):370–6.
20. Engel-Nitz NM, Sander SD, Harley C, Rey GG, Shah H. Costs and outcomes of noncardioembolic ischemic stroke in a managed care population. Vasc Health Risk Manag. 2010;6:905–13.
21. O’Sullivan AK, Rubin J, Nyambose J, Kuznik A, Cohen DJ, Thompson D. Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics. 2011;29(8):693–704.
22. Punekar RS, Fox KM, Richhariya A, et al. Burden of first and recurrent cardiovascular events among patients with hyperlipidemia. Clin Cardiol. 2015;38(8):483–91.
23. Department of Health and Human Services. Code of Federal Regulations: Protection of human subjects, Code Fed Regul Public Welfare. Title 45 (Sections 46-101 to 46-409). Washington, DC: USDHHS. 1995.
24. Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Clinical Modification. 2010. Available from: http://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed 28 Aug 2015.
25. Centers for Medicare and Medicaid Services. Healthcare Common Procedure Coding System. Available from: http://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/index.html?redirect=/medhcpcsgeninfo/. Accessed 28 Aug 2015.
26. US Department of Commerce, Economics, and Statistics Administration. US Census Bureau Census Regions and Divisions of the United States. Available at https://www.census.gov/geo/maps-data/maps/pdfs/reference/us_regdiv.pdf. Accessed 28 Aug 2015.
27. National Cholesterol Education Program Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in atherosclerosis. third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
28. US Department of Labor Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for All Urban Consumers (C-CPI-U) 1999–2012, Medical Care. Series ID: SUUR0000SAM. In: Department of Labor Bureau of Labor Statistics, ed. Washington, DC. 2013.
29. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epid. 2001;54(4):387–98.
30. Roberts CS, Gorelick PB, Ye X, Harley C, Goldberg GA. Additional stroke-related and non-stroke-related cardiovascular costs and hospitalizations in managed-care patients after ischemic stroke. Stroke J Cereb Circ. 2009;40(4):1425–32.
31. D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–81.
32. Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev. Gastroenterol Hepatol. 2010;7(9):485–94.